Literature DB >> 3698093

Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine.

G Murialdo, E Martignoni, A De Maria, M L Bonura, G Sances, G Bono, A Polleri.   

Abstract

Prolactin (PRL) responses to dopamine (DA) blockers and to direct and indirect DA agonists have been studied in 23 healthy women, 17 women with catamenial migraine and 17 with non-catamenial migraine in both their follicular and luteal phases. PRL responses to the DA blockers were greater in the follicular phase of both migraine groups than in controls. The inhibitory effect of nomifensine on PRL secretion was dampened in the follicular phase of both migraine groups. These findings demonstrate an increased PRL reserve in migraine and suggest the existence of a dopaminergic supersensitivity of the lactotrophic postsynaptic DA receptors. The impaired inhibitory effect of nomifensine on PRL secretion hints at a decrease of the presynaptic DA content in tuberoinfundibular DA neurons. In migrainous women 17-beta-oestradiol levels are higher in both ovarian phases, whereas progesterone concentrations and the progesterone to oestradiol ratio are lower than in healthy subjects in the luteal phase. These data suggest the existence of a change in the oestrogen-dependent modulation of pituitary DA receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698093     DOI: 10.1046/j.1468-2982.1986.0601043.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

1.  Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

Authors:  I Rainero; W Valfrè; L Savi; S Gentile; L Pinessi; L Gianotti; E Arvat; E Ghigo; P Del Rizzo; P Calvelli; P Limone
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

2.  Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.

Authors:  Megan S Rice; Pamela M Rist; Anke C Winter; Tobias Kurth; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2017-10-30       Impact factor: 7.396

3.  Migraine and breast cancer risk: a prospective cohort study and meta-analysis.

Authors:  Anke C Winter; Megan S Rice; Renée T Fortner; A Heather Eliassen; Tobias Kurth; Rulla M Tamimi
Journal:  J Natl Cancer Inst       Date:  2014-12-12       Impact factor: 13.506

4.  Flunarizine increases PRL secretion in normal and in migraineous women.

Authors:  U Bonuccelli; P Piccini; A M Paoletti; A Nuti; A Colzi; G B Melis; A Muratorio
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

5.  Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma.

Authors:  D Bosco; A Belfiore; A Fava; M De Rose; M Plastino; C Ceccotti; P Mungari; R Iannacchero; A Lavano
Journal:  J Headache Pain       Date:  2008-02-07       Impact factor: 7.277

6.  Soluble CD40 ligand and prolactin levels in migraine patients during interictal period.

Authors:  Sibel Guldiken; Baburhan Guldiken; Muzaffer Demir; Levent Kabayel; Hulya Ozkan; Nilda Turgut; Remziye Hunkar; Selahattin Kat
Journal:  J Headache Pain       Date:  2011-02-18       Impact factor: 7.277

7.  Serum prolactin and migraine.

Authors:  S Ali Masoud; E Fakharian
Journal:  Ann Saudi Med       Date:  2005 Nov-Dec       Impact factor: 1.526

8.  Chronic cluster-like headache in a patient with a macroprolactinoma presenting with falsely low prolactin levels: bromocriptine versus cabergoline?

Authors:  Maria M Pineyro; Gabriela Sosa; Maria R Finozzi; Natalia Stecker; Raul Pisabarro; Maria C Belzarena
Journal:  Clin Case Rep       Date:  2017-09-29

9.  Jealousy in women with migraine: a cross-sectional case-control study.

Authors:  Daphne S van Casteren; Florine A C van Willigenburg; Antoinette MaassenVanDenBrink; Gisela M Terwindt
Journal:  J Headache Pain       Date:  2020-05-11       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.